Key result
W1093A mutation in PMCA4b reduces calmodulin-activated pump inactivation half-time by ~99%.
Why the study?
The role of tryptophan 1093 in the calmodulin-binding/autoinhibitory domain of PMCA isoform 4b and its effect on pump activation and inactivation kinetics was unclear.
Tryptophan 1093 in PMCA4b primarily functions to slow the inactivation of the calmodulin-activated pump rather than playing a substantial role in Ca2+-calmodulin recognition.
W1093 primarily slows PMCA4b inactivation over CaM recognition; leaves open its relevance to cardiovascular calcium handling.
Tryptophan 1093 resides in the 28-residue calmodulin-binding/autoinhibitory domain of the plasma membrane Ca(2+) pump (PMCA). Previous studies with the isolated calmodulin-binding/autoinhibitory peptide from PMCA have shown that mutations of the tryptophan residue decrease the affinity of the peptide for calmodulin and its affinity as an inhibitor of proteolytically activated pump. In this study, the PMCA mutation in which tryptophan 1093 is converted to alanine (W1093A) was constructed in the full-length PMCA isoform 4b. The mutant pump was expressed in COS cells, and its steady state and pre-steady state kinetic properties were examined. The W1093A pump exhibited an increased basal activity in the absence of calmodulin, so the activation was approximately 2-fold (it is 10-fold in the wild type). The W1093A mutation also lowered the steady state affinity for calmodulin from K(0.5) of 9 nm for wild type to 144 nm (assayed at 700 nm free Ca(2+)). Pre-steady state measurements of the rate of activation by Ca(2+)-calmodulin revealed that the W1093A mutant responded 2.5-fold faster to calmodulin. In contrast to these relatively modest effects, the half-time of inactivation of the mutant was reduced by more than 2 orders of magnitude from 41 min to 7 s. We conclude that tryptophan 1093 does not play a substantial role in Ca(2+)-calmodulin recognition; rather it functions primarily to slow the inactivation of the calmodulin-activated pump.
No takes yet. Share an insight, caveat, or question.
Penheiter et al. (2002) studied this question. W1093A mutation in PMCA isoform 4b vs. Wild type PMCA isoform 4b was evaluated on Half-time of inactivation of the calmodulin-activated pump. The W1093A mutation in PMCA isoform 4b reduced the half-time of inactivation of the calmodulin-activated pump by more than 2 orders of magnitude, from 41 minutes to 7 seconds.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: